Fotivda (tivozanib) — Highmark
relapsed or refractory advanced renal cell carcinoma
Initial criteria
- age ≥ 18 years
- diagnosis of relapsed or refractory advanced renal cell carcinoma (ICD-10: C64)
- received at least two prior systemic therapies
relapsed or refractory advanced renal cell carcinoma